| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/16/2003 | WO2002067968A3 14-3-3 binding molecules as sensitizers for anticancer therapies |
| 01/16/2003 | WO2002043661A3 Recombinant anti-cd30 antibodies and uses thereof |
| 01/16/2003 | WO2002042445A3 Differentiated cells suitable for human therapy |
| 01/16/2003 | WO2002040540A3 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| 01/16/2003 | WO2002040016A3 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 01/16/2003 | WO2002036107A3 Treatment of motor fluctuations with 5-hydroxytryptamine 1a receptor activity enhancing coumpounds |
| 01/16/2003 | WO2002033044A3 Methods of high-throughput screening for internalizing antibodies |
| 01/16/2003 | WO2002031109A3 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 01/16/2003 | WO2002028388A3 Use of mek1 inhibitors as protective agents against damage due to ischemia |
| 01/16/2003 | WO2002022806A3 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses tehreof |
| 01/16/2003 | WO2002022171A3 Pharmaceutical composition having specific water activity |
| 01/16/2003 | WO2002022107A3 Pharmaceutical composition having modified carrier |
| 01/16/2003 | WO2002016587A3 Microtubule-associated proteins and tubulins |
| 01/16/2003 | WO2002012196A3 Lactam compounds and their use as inhibitors of serine proteases and method |
| 01/16/2003 | WO2002004021A9 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
| 01/16/2003 | WO2002002772A3 Human extracellular matrix (ecm)-related tumor marker |
| 01/16/2003 | WO2002002094A3 Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy |
| 01/16/2003 | WO2001098323A8 G-protein coupled receptors |
| 01/16/2003 | WO2001093913A3 T cell receptor fusions and conjugates and methods of use thereof |
| 01/16/2003 | WO2001092490A3 Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof |
| 01/16/2003 | WO2001085941A9 Myc targets |
| 01/16/2003 | WO2001070174A8 Vegf-modulated genes and methods employing them |
| 01/16/2003 | WO2001068123A9 Monocyte chemoattractant activity of galectin-3 |
| 01/16/2003 | WO2001064944A9 MODULATION OF PLEIOTROPHIN SIGNALING BY RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE β/$g(z) |
| 01/16/2003 | WO2001060315A3 Method for the treatment or prevention of flavivirus infections using nucleoside analogues |
| 01/16/2003 | WO2001052868A9 Combinations for treating neoplasms |
| 01/16/2003 | WO2001051049A9 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders |
| 01/16/2003 | US20030013771 Concurrent administering with drug; side effect reduction; central nervous system disorders |
| 01/16/2003 | US20030013770 Aminobenzophenones as inhibitors of il 1b and tnf |
| 01/16/2003 | US20030013766 Methods and pharmaceutical compositions for treatment of anti-estrogen resistant breast cancer using RXR Modulators |
| 01/16/2003 | US20030013759 Injection fatty acid, or salt thereof, into arteries |
| 01/16/2003 | US20030013745 Urazole compounds useful as anti-inflammatory agents |
| 01/16/2003 | US20030013739 Synergistic mixtures; side effect reduction |
| 01/16/2003 | US20030013733 Antihistamines, sleep disorders, central nervous system disorders |
| 01/16/2003 | US20030013728 Inhibitors of thrombin induced platelet aggregation |
| 01/16/2003 | US20030013720 Antidiabetic agents; obesity |
| 01/16/2003 | US20030013717 Cyclooxygenase inhibitor |
| 01/16/2003 | US20030013710 Sexual disorders |
| 01/16/2003 | US20030013703 Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization |
| 01/16/2003 | US20030013702 Agents and methods for treatment of cancer |
| 01/16/2003 | US20030013694 Prostate diseases |
| 01/16/2003 | US20030013689 Psychological disorders; synergistic mixture |
| 01/16/2003 | US20030013687 Pharmaceutical compositions and methods for treating anxiety, anxiety disorders and memory impairment using NAALADase inhibitors |
| 01/16/2003 | US20030013686 Bisphosphonate compound |
| 01/16/2003 | US20030013681 Complexing with galectins |
| 01/16/2003 | US20030013679 Polymer controlled induced viscosity fiber system and uses thereof |
| 01/16/2003 | US20030013675 Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases |
| 01/16/2003 | US20030013658 Small peptides and methods for treatment of asthma and inflammation |
| 01/16/2003 | US20030013654 Administering polypeptide |
| 01/16/2003 | US20030013652 Releasing moderators for inflammation |
| 01/16/2003 | US20030013638 P27 prevents cellular migration |
| 01/16/2003 | US20030013636 Prevent biosynthesis of galactoside |
| 01/16/2003 | US20030013170 Inhibitors of receptor activator of NF-kappaB and uses thereof |
| 01/16/2003 | US20030013144 Detection of modulator of cancer activity; obtain sample containing biopolymers, incubate with modulator, monitor cellular response |
| 01/16/2003 | US20030013143 Methods for identifying vasoprotective agents |
| 01/16/2003 | US20030013122 Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 01/16/2003 | US20030013097 Genes overexpressed in prostate disorders as diagnostic and therapeutic targets |
| 01/16/2003 | US20030013081 Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
| 01/16/2003 | US20030012827 May be administered in a purified form, or as part of a larger molecule, such as a glyceride that may be mixed, which releases free fatty acid after ingestion |
| 01/16/2003 | US20030012826 Carotenoids; vitamins E, D, & C; thiamine; riboflavin; niacin; folic acid; pyridoxine; biotin; pantothenic acid; cobalamin; magnesium; manganese; zinc; selenium; chromium; copper; alpha lipoic acid; and lutein; added iron free |
| 01/16/2003 | US20030012825 Metallized molecule therapies |
| 01/16/2003 | US20030012824 Orally administered anti-stress composition |
| 01/16/2003 | US20030012819 Method of preparing biological materials and preparations produced using same |
| 01/16/2003 | US20030012814 At least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. |
| 01/16/2003 | US20030012806 Drug releasing elastic band and method |
| 01/16/2003 | US20030012790 Especially bispecific molecules comprising an IFN- gamma inhibitor and a further specificity to a target involved in the initiation or development of IBD, including ulcerative colitis and Crohn's disease. |
| 01/16/2003 | US20030012787 Especially for ulcerative colitis and Crohn's disease. |
| 01/16/2003 | US20030012785 Intracellular drug delivery into an interleukin-2 receptor-bearing cell includes a chemical agent and a copy of an interleukin-2-receptor binding and endocytosis-inducing ligand bound to a water soluble polymer |
| 01/16/2003 | US20030012773 Diaper dermatitis preventative medication and a method for making and using same |
| 01/16/2003 | US20030012765 First polysaccharide crosslinked to second polysaccharide, selected from hyaluronic acid, dextran, dextran sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparin, heparan sulfate and alginate |
| 01/16/2003 | US20030012740 Aerosols especially containing benzotropine, pergolide, ropinerole, amantadine or deprenyl. |
| 01/16/2003 | US20030012739 Containing rosiglitazone maleate and a fluid carrier. |
| 01/16/2003 | US20030012737 Delivery of diphenhydramine through an inhalation route |
| 01/16/2003 | US20030012732 Feeding an ingestible substrate of radiolabeled microbeads and detecting an increase or decrease in ingested substrate as compared to that which has been ingested by a control nematode sample incubated without a candidate nematocide |
| 01/16/2003 | CA2490386A1 Method for producing analgesia comprising administration of an opioid receptor agonist in rotation with an opioid receptor like-1 receptor agonist |
| 01/16/2003 | CA2453572A1 The use of derivatives of 2,5-dihydroxybenxenesulphonic acids in the elaboration of a medicinal product to enhance the effect of other drugs used for the treatment of erectile disfunction |
| 01/16/2003 | CA2453173A1 Mycobacterial antigens expressed during latency |
| 01/16/2003 | CA2453075A1 Drug metabolizing enzymes |
| 01/16/2003 | CA2452590A1 Morpholine-bridged pyrazolopyridine derivatives |
| 01/16/2003 | CA2452501A1 Secreted proteins |
| 01/16/2003 | CA2452392A1 Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd) |
| 01/16/2003 | CA2452372A1 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 01/16/2003 | CA2452366A1 Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
| 01/16/2003 | CA2452241A1 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 01/16/2003 | CA2451742A1 Treatment of parasitic disease |
| 01/16/2003 | CA2451395A1 Novel pgc-1 isoforms and uses therefor |
| 01/16/2003 | CA2451092A1 Identification of modulators of neurotransmitter activity of xanthurenic acid |
| 01/16/2003 | CA2450502A1 Epf receptor assays, compounds and therapeutic compositions |
| 01/16/2003 | CA2450236A1 Phage displayed pdz domain ligands |
| 01/16/2003 | CA2447886A1 Compositions for removing human cerumen |
| 01/15/2003 | EP1275965A1 Method for identifying substances which modulate interleukin 4 (IL-4) signaling |
| 01/15/2003 | EP1275733A2 Assay methods for peptidase modulators |
| 01/15/2003 | EP1275720A2 Histidyl-trna synthetase of staphylococcus aureus |
| 01/15/2003 | EP1275638A1 Combination therapy for the treatment of immunological disorders |
| 01/15/2003 | EP1275400A1 Therapeutic composition of non MHC-restricted T-cells/NK-cells and MHC-restricted cells for the treatment of tumors |
| 01/15/2003 | EP1275399A2 Method and preparation for preventing and/or treating vascular disorders and secondary disorders associated therewith |
| 01/15/2003 | EP1275397A2 Medicament for local use |
| 01/15/2003 | EP1275392A2 Prolactin inhibiting or stimulating compounds to regulate the immune function |
| 01/15/2003 | EP1275375A1 Aerosol compositions |
| 01/15/2003 | EP1275372A1 Cosmetic or dermatological composition comprising a N-acylaminoamide derivative and a metalloproteinase inhibitor |